Europe
Patient Centric Approaches for Rare and Ultra-Rare Diseases
Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi, shares how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale....
Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!
Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar 'Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...
Virtual product launch planning: the ultimate playbook
We walk you through, step-by-step, how cross-functional teams can seamlessly work together and overcome the many obstacles associated with traditional product launches.
Genesis Research and Clinical Outcomes Solutions announce innovative partnership
International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes...
Genesis Research Acquires Market Access Transformation
Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),...
Data-driven policy and market access firm Avalere joins Fishawack Health
Fishawack Health bolsters its commercialization service offering with its largest addition to date, welcoming US-based policy, market access, and transformation leader Avalere.
Nucleus Global launches Chrysalis Medical Communications, the network’s newest agency brand in Europe, with a unifying mission
Nucleus Global, the largest specialist medical communications network in the world, today launched Chrysalis in Europe with the mission of transforming medical communications together.Stuart Gilbert, Managing Director, said: “Chrysalis’s mission...
Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)
Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed...
White paper: Are we prepared for the influx of CAR-Ts?
Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies
Report: Mexico’s drug market access landscape shake-up: What does it mean for pharma?
Rebeca Nana Barrantes and Tania Rodrigues outline what the shake-up in Mexico’s drug market access landscape means for pharma.